Nanohale AG (ETR:FYB) | WebDisclosure

Basculer en Français

10375	Companies
216275	Keywords
145952	Articles
114497	Press releases

Home
Companies
Nanohale AG

PRESS RELEASE

published on 10/30/2025 at 06:30, 6 months 12 days ago

Formycon invites to Conference Call on 2025 Nine-Month Results and announces Participation in Investor Conferences in the 4th Quarter of 2025
Formycon AG to discuss 2025 Nine-Month Results in Conference Call and participate in Investor Conferences. Company specializes in biosimilars for various disease areas

Financial Results Conference Call Investor Conferences Formycon AG Biosimilars
BRIEF

published on 10/21/2025 at 06:35, 6 months 21 days ago

Formycon lance le premier biosimilaire du ranibizumab en seringue préremplie en Europe

Teva Pharmaceuticals FYB201/Ranivisio® Biosimilaire Du Ranibizumab Seringue Préremplie Lancement De Formycon
BRIEF

published on 10/21/2025 at 06:35, 6 months 21 days ago

Formycon Launches Europe’s First Ranibizumab Biosimilar in Pre-filled Syringe

Teva Pharmaceuticals Ranibizumab Biosimilar Pre-filled Syringe FYB201/Ranivisio® Formycon Launch
PRESS RELEASE

published on 10/21/2025 at 06:30, 6 months 21 days ago

Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe
Formycon's FYB201/Ranivisio® is Europe's First Ranibizumab Biosimilar available in Pre-filled Syringe, offering improved handling, accuracy, and convenience for applicants. Teva to commercialize across Europe

Europe Biosimilar Formycon Teva Ranivisio
BRIEF

published on 10/16/2025 at 06:35, 6 months 26 days ago

Actor Pharmaceuticals and Megalabs Partner for FYB203 Commercialization

Formycon AG Eylea® Biosimilar Actor Pharmaceuticals Megalabs FYB203 Commercialization
BRIEF

published on 10/16/2025 at 06:35, 6 months 26 days ago

Actor Pharmaceuticals et Megalabs s'associent pour la commercialisation du FYB203

Formycon AG Biosimilaire Eylea® Megalabs Acteur Pharmaceutique Commercialisation Du FYB203
PRESS RELEASE

published on 10/16/2025 at 06:30, 6 months 26 days ago

Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 (aflibercept) for Australia and Latin America
Actor Pharmaceuticals and Megalabs to commercialize Formycon's Eylea biosimilar FYB203 in Australia and Latin America. Partnership agreements include upfront payments and royalties

Partnerships Commercialization Biosimilar Formycon Eylea
BRIEF

published on 10/02/2025 at 06:35, 7 months 9 days ago

Formycon Secures U.S. License for Aflibercept Biosimilar

Formycon AG U.S. Market Launch Aflibercept Biosimilar Regeneron Agreement Patent Dispute Resolution
BRIEF

published on 10/02/2025 at 06:35, 7 months 9 days ago

Formycon obtient une licence américaine pour le biosimilaire d'Aflibercept

Formycon AG Lancement Sur Le Marché Américain Biosimilaire D'Aflibercept Accord Regeneron Résolution Des Litiges En Matière De Brevets
PRESS RELEASE

published on 10/02/2025 at 06:30, 7 months 9 days ago

Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron. Commercial launch expected in Q4/2026

Formycon Regeneron Valorum Biologics Aflibercept Biosimilar Patent Disputes

Accesswire

Published on 05/11/2026 at 08:05, 55 minutes ago

Tocvan Accelerates Gran Pilar: 5,000+ Meters Drilled to Date, Historic Workings Discovered on South Block, Pilot Progresses
Published on 05/09/2026 at 01:55, 2 days 7 hours ago

Prospect Ridge Announces Board Resignation
Published on 05/09/2026 at 01:40, 2 days 7 hours ago

Findev Inc. Issues Corrective Disclosure
Published on 05/09/2026 at 01:30, 2 days 7 hours ago

Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 2 days 9 hours ago

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology

View all ACCESSWIRE

EQS Group

Published on 05/11/2026 at 08:40, 20 minutes ago

ZPMC Renews "Shanghai Brand" Certificate No. 001 for 3E-Class Ship-to-Shore Cranes
Published on 05/11/2026 at 08:30, 30 minutes ago

Viromed Medical AG: ViroCAP® med successfully completes regulatory process as a Class IIa medical device – starting signal for market launch at the European Wound Congress 2026
Published on 05/11/2026 at 08:30, 30 minutes ago

Eurobattery Minerals secures SEK 60 million convertible bond facility and draws first tranche of SEK 10 million
Published on 05/11/2026 at 08:30, 30 minutes ago

2G Energy AG has rescheduled the release of preliminary figures for mid-June 2026. ERP closing procedures at the newly established production company are taking longer than planned.
Published on 05/11/2026 at 08:05, 55 minutes ago

SWI Capital - Convocation of annual general meeting of shareholders

Les Echos

Published on 05/07/2026 at 19:15, 3 days 13 hours ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 3 days 13 hours ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 3 days 13 hours ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 3 days 13 hours ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 3 days 14 hours ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE